Immunotherapy Changes First-Line Paradigm in Advanced RCC – Medscape
Medscape |
Immunotherapy Changes First-Line Paradigm in Advanced RCC
Medscape New data are set to change the paradigm for the first-line treatment of advanced renal cell carcinoma (RCC), after a phase 3 trial showed significantly improved overall survival (OS) with immunotherapy in comparison to standard care with sunitinib … |
